Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in-vivo editing.
Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is a Malaria No More “10 to END” innovator.
While still a graduate student at Stanford, Trevor launched Mammoth Biosciences, recruited Nobel Laureate Jennifer Doudna, secured a license from Berkeley, and signed a lease with MBC BioLabs – not a bad start for a first-time 28 year-old entrepreneur. Since then Mammoth has raised $68mm to develop its CRISPR diagnostics platform, formed partnerships with GSK for COVID testing, as well as partnerships Millipore Sigma, and Agilent. Now he’s a Forbes 40-Under-40 and Executive of the Year with the San Francisco Business Times.